Recounting the 2019 Kansas City Chiefs historic run to a Super Bowl Championship – Arrowhead Addict

(Chiefs) MIAMI, FLORIDA FEBRUARY 02: Head coach Andy Reid of the Kansas City Chiefs celebrates with the Vince Lombardi Trophy after defeating the San Francisco 49ers 31-20 in Super Bowl LIV at Hard Rock Stadium on February 02, 2020 in Miami, Florida. (Photo by Kevin C. Cox/Getty Images)

This is why were here, dog! You remember that stretch we had in September and October? We knew what team we was, dog! All we had to do was believe in each other and play for each other! I watched a lot of yall drop yall pride this year, dog! I watched a lot of people step up, big time players. Thats what we need today, we need energy, we need oneness. We need to be remembered! Lets go! Tyrann Mathieus (Super Bowl pregame speech)

Immortality. The ability to live forever, even after you have physically passed on from this life. Its a philosophical prospect in life, finding its place in discussions mostly carried on by those of religious presuppositions.

The other place it is often discussed is in sports, often at the end of a season when a players or teams exploits are compared with those from past years and generations now long gone. To obtain a seat at this table of discussion, you must first do something special. You must be a champion. Every member of the 2019 Kansas City Chiefs has just achieved that very requirement.

With 11 minutes and 57 seconds left to go, it didnt seem this ending was probable. The Chiefs offense had fought valiantly, but their normally precise general had made some uncharacteristic mistakes. Some werent surprised. After all, the 49ers defense was one of the best in the league and arguably the best the Chiefs had faced all season. Down the same number of points they had scored in the prior 48 minutes and 3 seconds, the incredible 2019 season seemed on the doorstep of defeat.

Yet the once maligned Chiefs defense stared in the face of competitive death and determined itself unwilling to be overcome. Frank Clark would later recall how angry it had made him seeing the 49ers players celebrating on the sideline, prematurely. With 11 minutes and 57 seconds left, the Niners defense would make what appeared a game sealing interception. The sidelines jubilation was apparent; they thought they had won the game.

With an undying belief of destiny that had formed amongst the Chiefs locker room early in the teams late-season winning streak, now spilling over the threshold of the players minds in the teams darkest moments, Clark let the 49ers offense know what he thought. Theyd be going home disappointed.

The Chiefs, with 10 minutes and 20 seconds and counting. This is a critical drive for them right now, obviously they have to make a stop. They have to make a stop right now! Troy Aikman

The 49ers, a vaunted offense in their own right, would never score again. A Chiefs defense that was an embarrassment a year prior, retooled in every way imaginable, would do everything Chiefs Kingdom could have asked for and more. A league MVP, subdued for three and a half quarters but his iron will still resolute, along with his cohort of talented skill players would unleash one of the greatest scoring onslaughts in Super Bowl history.

As the final seconds ticked away and the red and gold confetti began to rain on the field at Hard Rock Stadium, it was finally clear how special this 2019 Chiefs team is, was and forever will be regarded. Andy Reid, Patrick Mahomes, Clark Hunt, and a host of other Chiefs would raise the Lombardi Trophy thanks to legendary feats throughout the year and playoffs.

Obviously, the Chiefs late season push for their first Super Bowl victory in 50 years makes this the most memorable season in decades. That goes without saying. However, there are a handful of reasons why this particular run is so memorable aside from the championship.

Go here to read the rest:
Recounting the 2019 Kansas City Chiefs historic run to a Super Bowl Championship - Arrowhead Addict

Jenny Offill’s Novel Weather Looks at "Climate Dread" with Humor and Plenty of Gloom – TheStranger.com

Author photo by Emily Tobey

If you are not already experiencing "climate dread," the feeling that you're living in a slow-mo ecological apocalypse that you're powerless to stop, then Jenny Offill's latest novel, Weather, will fill you to the brim with it.

Granted, your capacity to care about "climate dread" may be reduced if you're currently suffering from rent-hike dread, hospital-bill dread, getting-shot-by-the-cops dread, and inability-to- retire dread, and that diminished capacity may prevent you from diving into Offill's sustained meditation on the subject. However, if you are a little curious about it, her black humor and occasionally deep insights will keep your eyeballs glued to the page in search of a cure.

Weather has much in common with Offill's last book, Dept. of Speculation. Both enjoyed lots of pre-publication love on social media from the New York publishing industry's tastemakers. Both present a domestic fiction using literary collage, a technique popularized most recently by nonfiction writers/poets such as Maggie Nelson and Claudia Rankine. And both are overhyped but still very much worth a read.

In Weather, Offill places the reader in the mind of Lizzie, a librarian in the big city with a supportive partner and a "gifted and talented" kid in school. In short, diaristic, pithy but breezy paragraphs, we learn that Lizzie spends a lot of time caring for her brother as he struggles with addiction, worrying about her child's future on a doomed planet, and reflecting on the pleasures and temptations of married life. When she takes a side gig answering e-mails for her former writing teacher's doomsday podcast, her focus on climate dread and prepping for the end-times begins to consume her, and the narrative gains steam.

Fans of NYC dinner-party zingers and stumbled-upon profundities will appreciate Offill's contributions to the field. Some of the funnier moments in the book come at the expense of wide-eyed businessmen whose devotion to technology allows them to escape the cold reality of a warming planet. "These people long for immortality but can't wait ten minutes for a cup of coffee," Lizzie's mentor quips at one point. The more profound moments arrive in Lizzie's fervent search for new perspectives to combat her growing dread, though these new perspectives aren't always comforting:

"Young person worry: What if nothing I do matters?

Old person worry: What if everything I do does?"

Though some of Offill's jokes and profundities can feel a bit pat, the overall structure of the book is greater than the sum of its parts, offering readers the pleasure of looking back through a diary and realizing that all our apparently disparate anxieties may fall under the umbrella of the larger one: fear of extinction.

Weather suggests that climate dread is its own crisis, a collective psychological block preventing us from taking the action necessary to stave off ecological collapse or, at the very least, to manage it more effectively.

Though fiction can allow us to diagnose this problem in all its messy human nuance, Offill knows it can never give us the cure. To that end, she concludes her story with an obligatory note of hope that lies outside the book itself, literally a website URL: http://www.obligatorynoteofhope.com. The site appears to be a place where climate-dreaders, or people who caught the disease from the book, can connect and take collective action to dig each other out of the doldrums.

Read the original post:
Jenny Offill's Novel Weather Looks at "Climate Dread" with Humor and Plenty of Gloom - TheStranger.com

WIN a Copy of ‘Doctor Sleep’ with the Director’s Cut on Blu-ray + Digital! – Bloody Disgusting

Easily one of the best horror movies of last year,Mike FlanagansDoctor Sleepis now available on VOD platforms, as well as 4K Ultra HD and Blu-ray. The release includes the highly anticipated extended Directors Cut, which is 3-hours long (180-minutes), compared to the 152-minute theatrical cut.

Bloody Disgusting has (2) Blu-ray copies +Digital for some lucky readers to enter and win. All you have to do is fill out the below form. Winners will be chosen at random. No PO boxes. U.S. only.

Doctor Sleep is an adaptation of Stephen Kings same-titled novel as well as a sequel to Stanley Kubricks The Shining. Ewan McGregorleads the cast as an adult Danny Torrance, withRebecca Fergusonas Rose the Hat,Kyliegh Curranas Abra Stone, andAlex Essoeas Wendy Torrance.

InDoctor Sleep, still irrevocably scarred by the trauma he endured as a child at the Overlook, Dan Torrance has fought to find some semblance of peace. But that peace is shattered when he encounters Abra, a courageous teenager with her own powerful extrasensory gift, known as the shine. Instinctively recognizing that Dan shares her power, Abra has sought him out, desperate for his help against the merciless Rose the Hat and her followers, The True Knot, who feed off the shine of innocents in their quest for immortality.

Forming an unlikely alliance, Dan and Abra engage in a brutal life-or-death battle with Rose. Abras innocence and fearless embrace of her shine compel Dan to call upon his own powers as never beforeat once facing his fears and reawakening the ghosts of the past.

Read the rest here:
WIN a Copy of 'Doctor Sleep' with the Director's Cut on Blu-ray + Digital! - Bloody Disgusting

A Cyberpunk 2077 Themed Xbox One Controller Could Be On Its Way – Player.One

South African retailerRaru has recently listed a new product that suggestsa Cyberpunk 2077 themed Xbox One controller is in the works. The discovery was first found by a Reddit user, who shared a screenshot of the website that refers to "Microsoft - Xbox One Wireless Controller - Cyberpunk 2077 Limited Edition (Xbox One/Windows 10)", though there are no images that accompany the information.

Talking about Raru, it is a reputable retailer in Africa, which meansthisinformation is likely notfake. Additionally, we are not surprised seeing gaming peripherals being themed in Cyberpunk 2077 skins as the release nears.

The product description on the page only suggests that it is a standard Xbox One controller, though I still hope that Microsoft comes up with a futuristic and dystopian skin for the controller itself.Now that the possibility of anXbox One controller themed with the game's skin has been found, it also suggests that a Cyberpunk 2077 limited editionXbox One console could be on the way. However, there isn't any information about whether a PlayStation variant is in the works or not.

Since we are on the topic of Cyberpunk 2077, developer CD Projekt Red has delayed the game's launch to September of this year. The game was originally set to release in April, but due to some polishing work that neededto be done, the game had to bedelayed.

Cyberpunk 2077 is an open-world, action-adventure RPG game set in a fictional Night City.Night City is a megalopolis obsessed with power, glamour and body modification. You step into the shoes ofmercenary outlawV, who is going after a one-of-a-kind implant that is the key to immortality.Cyberpunk 2077 lets you customize your characters cyberware, playstyle, and skillset. Your choices in the game will shape the world around you.

Cyberpunk 2077is set to launch on PC, PS4, and Xbox One in September.

Original post:
A Cyberpunk 2077 Themed Xbox One Controller Could Be On Its Way - Player.One

The Mysteries of the Sh’ma – Mosaic

From when does one read the shma in the evening?Opening words, Mishnah and Talmud

Hear, O Israel: the Lord our God, the Lord is One.

This simple sentence in the Hebrew Bible, known by its first word as the shma (hear), is also the first subject addressed in the Talmud and the first biblical verse taught to Jewish children. It is, at once, the most famous affirmation of Jewish belief and the most misunderstood. To appreciate this paradox, we must begin with the text itself, two of whose three brief sections make up a key element in Moses string of passionate valedictory charges to his people in the book of Deuteronomy. Here is the first section (6:4-9), in which the greatest of prophets sums up Jewish theology:

Hear, O Israel: The Lord our God, the Lord is One. And thou shalt love the Lord thy God with all thy heart, and with all thy soul, and with all thy might. And these words, which I command thee this day, shall be in thy heart. And thou shalt teach them diligently unto thy children, and shalt talk of them when thou sittest in thy house, and when thou walkest by the way, and when thou liest down, and when thou risest up.

From the words urging that this teaching be recited when thou liest down, and when thou risest up came the central inclusion of the shma in, respectively, the evening and morning liturgy. And yet, in reciting it, Jews for millennia have added another sentence immediately after the first, and before proceeding to the rest. It is a sentence that appears neither in Deuteronomy nor anywhere else in the Bible and that, notably, is recited in a hushed tone, thereby signaling that it is both a part of and apart from the shma prayer as a whole:

Blessed be His glorious sovereign Name, for ever and ever.

Needless to say, the addition of this sentencethe exact date of its inclusion is unknowndid not evade the gimlet-eyed exegesis of the talmudic sages, who were struck by its oddity. Why is it there in the first place, and, if it is part of the liturgy, why not recite it aloud? In responding, the Talmud tells a tale, according to which the shma originated not with Moses but long before him: with his ancestors, and specifically with one of the biblical patriarchs and his family.

The story goes like this: at the end of his days, Jacob, as described in Genesis, gathers all twelve of his sons around him. Feeling his life and his powers of prophecy slipping away, he expresses concern that one of his children might abandon the Abrahamic mission (something that had already occurred with a child of Abraham himself as well as with a child of Isaac). Seeking to reassure their father on this point, his sons address him by the covenantal name bestowed upon him by an angel (Genesis 32: 22-32). The rabbis explain:

His sons said to him: Hear, Israel our father, the Lord is our God, the Lord is One. They were saying that just as there is only one God in your heart, so, too, there is only one in our hearts. At that moment Jacob our father, [reassured that all of his children were righteous], replied in praise: Blessed be His glorious sovereign Name for ever and ever. (Psaim 56a)

For the rabbis, Jacobs relieved exclamation linked the Almightys eternity with his own. That is to say: Gods name will be blessed forever because Jacobs family will serve Him forever. Now included in the shma prayer, this same sentence links Gods immortality with the posterity of every Jewish family. Because the words are not actually those of Moses, the rabbis stipulate that the sentence is to be voiced quietly.

This rabbinic story and its accompanying explanation have been embraced in Jewish law as the normative foundation for the shma as it has been recited until today. Even Maimonides, who so often reads talmudic tales as other than literal, included the ruling in the Mishneh Torah, his code of Jewish law.

In short, in the recitation of the shma, two different statements from two different moments in biblical history are being made simultaneously. In one and the same act, Jews quote the words of Moses speaking to the people of Israel and then the response to the twelve sons by their father Jacob, the original Israel. In the first, the shma is a theological-political statement; in the second, it is an assurance of Jewish continuity. The first is philosophical, the second familial; the first is public and ceremonial, the second private and emotional. Even as Hear O Israel is being sounded aloud, Jews quietly reaffirm their solidarity with the patriarch and his children.

That latter commitment is reenacted with particular force and poignancy in the longstanding practice of reciting the shma before sleep at night. For Jewish parents putting their children to bed and saying it together with them, few rituals are more powerful. At that moment, we are uniquely aware that our children will not always be small and safe under our protection, and that one day we in turn will become dependent on them, and on the family they perpetuate, for our own immortality. As Rabbi Norman Lamm once put it, in saying the shma aloud and then, quietly to ourselves, blessed be His glorious sovereign name for ever and ever, we, just like Jacob, and together with our own progeny, play our part in ensuring that Gods name will continue to be blessed here on earth.

And therein lies another lesson, this one about the nature of Judaism itself. For this purpose, we can compare the Talmuds tale about Jacob and his sons, about the recovery by a dying Jewish patriarch of his familys immortality, with the account of another famous deathbed scene in the ancient world.

In that account, related by Plato in the Phaedo, the Greek philosopher Socrates finds himself on the brink of death in an Athenian cell, attended by his students, pondering his legacy, and reviewing with them the great issues that had long absorbed his mind, not least the immortality of the soul. Serenely he assures these students that he welcomes his impending, self-inflicted death by hemlock as a release from the bonds of physicality that are the curse of earthly humanity. Freed from the constraints of the body and its passions, Socrates hopes for an afterlife happily occupied with the contemplation of eternal verities.

One could hardly imagine a starker contrast between two men. Socrates is wholly absorbed in his students and in his own immortal soul; he seems utterly uninterested in his family, calmly dismissing his wife and their baby son with nary a tear or emotional farewell. Jacob, the father who in creating and rearing faithful children has united his physical life with his spiritual legacy, commands those children to bear his lifeless body to the Holy Land. By rooting it in sacred soil, he will have prepared the way for the eventual return of his offspring to their national home.

As Eric Cohen has written, for all its renown, the death of Socrates seems less fully human than the death of Jacob, which unites the private drama of father and sons with the public drama of Israels beginnings as a nation. Just so; and in contrasting these two very different deaths, Cohen also points to one of the central differences between Greek and Jewish civilization.

In Aristotelian texts, the family merely provides preparation for service to the polis, and the great-souled man embodies the ideal of excellence. Plato goes farther, having Socrates declare in his Republic that in the truly just city, the philosopher-king will produce anonymous offspring whom he will pointedly not raise as his own lest he thereby compromise the universal compassion for all citizens that justice requires.

This, to a Jew, could not be more distant from Gods explanation for his choice of Abraham: For I have known him, that he will command his children and household after him, to keep the ways of the Lord, to perform righteousness and justice (Genesis 18:19). For Jews, the domain of the family is where the blood bond and the spiritual bond are joined, where transmission takes place, where children are taught about the God of their fathers, where the realm of the truly sacred and the truly human conjoin.

The Greek world is not the Jewish world; even attempts to find similarities reveal more about the differences. Take, for example, the frequent likening of the Passover seder to the Greek symposium. Both meals involve a choreographed series of imbibings and a discussion of philosophical and theological subjects.

And yet: would a Greek symposium welcome children, much less focus on them? Is a single child to be found in Platos Symposium? On the contrary, we find the best and the brightest of Greek society: Socrates is there; Alcibiades is there, physicians and philosophers, scholars and statesmen are there. No one has brought his progeny; to do so would ruin the conversation.

The ritual of the seder, for its part, though it may seem superficially Greco-Roman, is actually the inverse: it is all about children and family. In the Haggadah, philosophical inquiry is balanced by imaginative storytelling and covenantal re-creation. Father and mother teach children about the Almighty taking to Himself a people, and in going to sleep the children joyously respond: Hear O -Israel-Father, the Lord our God, the Lord is one.

This, finally, returns us to the opening question of the Talmudfrom what time may one recite the shma in the evening?and its seemingly technical answer: from the time that the priests enter to eat their trumah.

The reference in the final word is to the end of twilight, when the priests of the Temple are once again permitted to partake of food they may eat only while ritually pure. But if thats when recitation of the shma can begin, what is the last point at which it can still be recited? Here a debate emerges, with three opinions followed by a story:

Until the end of the first watch. These are the words of Rabbi Eliezer.The sages say: until midnight. Rabbi Gamliel says: until the dawn comes up. Once it happened that [Gamliels] sons came home [late] from a wedding feast and they said to him: we have not yet recited the [evening]shma. He said to them: if the dawn has not yet come up, you are still bound to recite. . . . Why, then, did the sages say until midnight? In order to keep a man far from transgression. (Brakhot 2a).

The children of Gamliel, arriving after midnight but before dawn, and therefore assuming that, since the law accorded with the sages, they could no longer fulfill their obligation, are informed by their father that the sages established midnight only as an ideal deadline, in order to encourage early recital; but as long as dawn has not occurred, the commandment can still be obeyed.

Stop for a moment and consider who is telling this story. The author of the Mishnah is Rabbi Judah the Prince, a grandson of none other than Rabbi Gamliel. Judahs story therefore concerns his own father and uncles interacting with their father. This small succinct story thus shares a subject with the shma itself: the subject, that is, of familial fidelity.

Where, Rabbi Judah is asking, is true wisdom to be found? Gamliels sons have been to a drinking party: the term is often rendered as a wedding, but no textual evidence supports such a reading. More likely, in the Greco-Roman world in which the Mishnah was composed, it referred to a symposium, an event at which, by the lights of that culture, true sophistication and wisdom were to be found. Yet, for these aspiring young rabbis, the symposium has caused them to forget the central obligation of Jewish life. They arrive home thinking that the deadline has passed and contritely confess that they have failed.

At that point, new wisdom is transmitted from parent to child: it is not too late. In the darkness before dawn, this family can still give full-throated voice to the foundational words of Jacobs sons to their father Israel: Hear O Israel-Father, the Lord our God, the Lord is One.

That is why the practices and regulations surrounding this sentence, than which no other sentence is more powerful, are the very first matter taken up by the rabbis of the Talmud, and why it is the sentence occupying so central a place in every evening and morning prayer service, the sentence proclaimed in their dying breath by martyrs throughout history, the sentence repeated in gratitude and joy with children as they drift off to sleep, the sentence uttered as one prepares to bid farewell to this world, sanctifying the Lords name for ever and ever.

See the rest here:
The Mysteries of the Sh'ma - Mosaic

Near Dark Is a Better 1980s Vampire Movie Than The Lost Boys – Screen Rant

1987 vampire movies Near Dark and The Lost Boys are both great in different ways, but the former tends to get brushed aside in favor of the latter. Outside of perhaps the ghost, demon, and zombie, vampires are the monster with the most movies and TV shows made about them. There's something naturally alluring about vampirism, with its ability for those turned to live forever, perform inhuman physical feats, and often possess supernatural powers that allow for easy mental manipulation. Some vampires can even shape-shift at will.

Of course, there are certain downsides to vampirism, with the most obvious being the need to consume blood to survive, presumably via the killing of humans. Immortality can also kind of be a drag, especially if one opts to fall in love with or become friends with a mortal person they will one day have to watch die. Being a vampire is a bit of a double-edged sword, and Near Dark and The Lost Boys both alternately represent opposite sides of that coin, displaying both the seductive power and freedom offered by the condition, and its not-so-pleasant side effects.

Related: Stephen King's Salems Lot Changed Vampire Movies

Since they came out in the same year, it's common for horror fans to end up discussing both Near Dark and The Lost Boys when talking about the vampire movies of the 1980s. Unfortunately, Near Dark doesn't seem to get nearly the level of respect as The Lost Boys, and that's not fair.

To be clear, Near Dark being better than The Lost Boys doesn't make the latter a bad film. It's a lot of fun, and has a rocking, 1980s party atmosphere. At the same time, the story is kind of superficial, and the movie is often more concerned with being visually arresting than delving into its characters. The vampire group in Lost Boys is also a bit too large, with everyone not played by Keifer Sutherland or Jami Gertz basically blending together. The makeshift vampire family in Near Dark is much more memorable on an individual basis, with the wild and unpredictable big brother Severen (Bill Paxton), the wise but vicious father figure Jesse Hooker (Lance Henriksen) and mother figure Diamondback (Jeanette Goldstein), the unwilling child Homer (Joshua John Miller), and the sweet but forlorn Mae (Jenny Wright).

There's also the protagonist that finds themselves becoming a vampire after falling for a beautiful female bloodsucker in both films. The Lost Boys' Michael, as played by Jason Patric, really isn't given much to do outside of brood and be scared. Near Dark's Caleb, as played by Adrian Pasdar, actually begins to care for and about his new family, and for a while, accepts that his new lot in life is to be part of their ranks.

Finally, as a horror film, Near Dark is much more effective. Lost Boys often diffuses its best horror bits with laughs, while Near Dark takes things quite seriously, and doesn't hesitate to get gory and harsh. The score by Tangerine Dream is also excellent, providing a moody, dreamlike feeling to the proceedings. Near Dark also features a novel cure for vampirism, involving a blood transfusion, while The Lost Boys mostly sticks to normal lore. The Lost Boys is and was a blast, but when it comes to the better 1980s vampire film, Near Dark wins.

More: Where Are They Now? The Cast Of The Lost Boys

Saw: Amanda Young Became The Main Killer In Dead By Daylight

Michael Kennedy is an avid movie and TV fan that's been working for Screen Rant in various capacities since 2014. In that time, Michael has written over 2000 articles for the site, first working solely as a news writer, then later as a senior writer and associate news editor. Most recently, Michael helped launch Screen Rant's new horror section, and is now the lead staff writer when it comes to all things frightening. A FL native, Michael is passionate about pop culture, and earned an AS degree in film production in 2012. He also loves both Marvel and DC movies, and wishes every superhero fan could just get along. When not writing, Michael enjoys going to concerts, taking in live professional wrestling, and debating pop culture. A long-term member of the Screen Rant family, Michael looks forward to continuing on creating new content for the site for many more years to come.

Link:
Near Dark Is a Better 1980s Vampire Movie Than The Lost Boys - Screen Rant

The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean – BioSpace

WASHINGTON, D.C., Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today released the agenda for its second annual Cell & Gene Meeting on the Mediterranean. The event will be held from April 15-17, 2020 in Barcelona, Spain.

The event, modeled after ARMs highly successful Cell & Gene Meeting on the Mesa, is expected to attract more than 500 attendees, including senior executives from leading cell therapy, gene therapy, and tissue engineering companies worldwide, large pharma and biotech representatives, institutional investors, academic research institutions, patient foundations, disease philanthropies, and members of the life science media community.

The agenda includes:

Plenary Session:

Keynote Address:

Panels:

Throughout the two-day event, participants can also attend presentations by more than 50 publicly traded and emerging private companies, highlighting clinical and commercial progress in cell therapy, gene and gene-modified cell therapy, tissue engineering, biomaterials and more. In addition to their presentations, representatives from these organizations will also be available for one-on-one partnering opportunities throughout the conference.

2020 presenting companies include: Adaptimmune, AGTC, Ambys Medicines, AskBio, Aspect Biosystems, Atara Biotherapeutics, Autolus Therapeutics, Avectas, AVROBIO, Axovant Gene Therapies, bluebird bio, Bone Therapeutics, Cabaletta Bio, Caribou Biosciences, Celavie Biosciences, Cellatoz Therapeutics, Cellect Biotherapeutics, CEVEC, Cryoport, Cynata Therapeutics, Flexion Therapeutics, Fraunhofer IZI, Genethon, GenSight Biologics, Healios, Iovance Biotherapeutics, Kiadis Pharma, Kytopen, LogicBio Therapeutics, MeiraGTx, Minerva Biotechnologies, MolMed, Novadip Biosciences, Orchard Therapeutics, Oxford Biomedica, PDC*line Pharma, Polyplus-transfection, Precision BioSciences, Promethera Biosciences, PTC Therapeutics, Recombinetics, REGENXBIO, ReNeuron, Rexgenero, Sangamo, SmartPharm Therapeutics, Standards Coordinating Body for Regenerative Medicine, Theradaptive, ThermoGenesis, Tmunity Therapeutics, Ultragenyx Pharmaceutical, VERIGRAFT, and Vineti.

For full details on the agenda and further information about the event, please visit http://www.meetingonthemed.com.

Registration is complimentary for credentialed members of the media. For members of the media interested in attending, please contact Kaitlyn Donaldson Dupont at kdonaldson@alliancerm.org or Consilium Strategic Communications at ARM@consilium-comms.com.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory, and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. Founded in 2009, ARM works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its 350+ member organizations worldwide. ARM represents the interests of therapeutic developers, academic research institutions, major medical centers, investors, and patient groups that comprise the broader regenerative medicine community and is the prominent international advocacy organization in this field.

ARM has 70+ members across 15 countries in Europe. ARM aims to work closely with European stakeholders, leveraging its membership to create a supportive commercial and regulatory environment to create better conditions for the development and commercialization of ATMPs in Europe; develop strong stakeholder support around proposed solutions to improve patient access to ATMPs; promote clear, predictable and efficient regulatory framework across Europe; and promote international convergence of key regulations and guidance. For more information, visit alliancerm.org.

Continue reading here:
The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean - BioSpace

ABCA7 Gene Expression and Genetic Association Study in Schizophrenia | NDT – Dove Medical Press

Kiyohiro Yamazaki,1 Yuta Yoshino,1 Kentaro Kawabe,1 Tomomasa Ibuki,1 Shinichiro Ochi,1 Yoko Mori,1 Yuki Ozaki,1 Shusuke Numata,2 Jun-ichi Iga,1 Tetsuro Ohmori,2 Shu-ichi Ueno1

1Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan; 2Department of Psychiatry, Course of Integrated Brain Sciences, Medical Informatics, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima 770-8503, Japan

Correspondence: Jun-ichi IgaDepartment of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, JapanTel +81-89-960-5315Fax +81-89-960-5317Email iga.junichi.it@ehime-u.ac.jp

Introduction: Although ATP-binding cassette sub-family A member 7 gene (ABCA7) is known to be associated with Alzheimers disease, the relationship between ABCA7 and schizophrenia has been unknown.Methods: Schizophrenia patients (n = 50; 24 males, 62.1 0.50 years old) and age- and sex-matched healthy controls (n = 50) were recruited for the mRNA analysis. Additionally, a case-control study for the rs3764650 genotypes was performed with 1308 samples (control subjects; n = 527, schizophrenia patients; n = 781). All participants were Japanese, unrelated to each other, and living in the same area.Results: The distributions of the rs3764650 genotypes in schizophrenia patients were not different from that of controls. However, the ABCA7 mRNA expression levels in schizophrenia patients were significantly higher than those in controls by a logistic regression analysis. Additionally, the ABCA7 mRNA expression levels in schizophrenia patients were correlated with the rs3764650 genotypes in a dose-dependent manner.Discussion: The ABCA7 mRNA expression levels in peripheral blood with the rs3764650 genotypes may be related to pathological mechanisms in schizophrenia and may be a biological marker for schizophrenia.

Keywords: schizophrenia, ATP-binding cassette sub-family A member 7 gene, single nucleotide polymorphism, rs3764650, mRNA expression

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original:
ABCA7 Gene Expression and Genetic Association Study in Schizophrenia | NDT - Dove Medical Press

Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion – Yahoo Finance

- Salvador Rico, M.D., Ph.D., named Chief Medical Officer

- Martin Moorhead, Ph.D., promoted to Chief Technology Officer

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 /PRNewswire/ --Encoded Therapeutics, Inc.(Encoded), a precision gene therapy company,today announced the appointment of Salvador Rico, M.D., Ph.D., as chief medical officer and the promotion of Martin Moorhead, Ph.D., to chief technology officer. Dr. Rico joins Encoded from Audentes Therapeutics, where he led clinical development of the company's pipeline of gene therapies for neuromuscular disorders. In his three years at Encoded, Dr. Moorhead has guided the development of the company's technology platform for creating innovative AAV-based gene therapies. He previously led the development of clonoSEQ, the FDA-approved next-generation sequencing assay for detecting minimal residual disease in lymphoid malignancies, at Adaptive Biotechnologies.

Encoded Therapeutics, Inc. Logo (PRNewsfoto/Encoded Therapeutics, Inc.)

"Sal is an accomplished physician-scientist with deep experience advancing novel therapeutics through clinical development, and Martin is a strong leader who brings a genomics mindset to all aspects of gene therapy development," said Encoded co-founder and chief executive officer Kartik Ramamoorthi, Ph.D."With these appointments, we now have some of the most qualified gene therapy experts in the industry with a proven track record of delivering for patients in need. Their collective experience includes bringing multiple AAV-based gene therapies through clinical development, FDA filings, and approval. I am more confident than ever that our novel gene therapies can make a major impact on patients suffering from debilitating diseases, starting with Dravet Syndrome."

At Encoded, Dr. Rico will lead medical strategy and clinical development of ETX101, which is being developed for patients with SCN1A+ Dravet Syndrome. Dr. Moorhead will lead the technical team that enables Encoded's innovative research platform.

"I am delighted to join an organization that is so committed to transforming patients' lives with the development of next-generation gene therapies," said Dr. Rico. "I look forward to working closely with both the team at Encoded, and with the Dravet Syndrome community, to advance ETX101 through clinical development and ultimately, deliver it to patients in need."

"In building a technology platform that combines the power of genomics and computation with AAV-based gene therapy, Encoded is forging the path for the next generation of precision genetic medicines," said Dr. Moorhead. "I am very proud of what we have accomplished to date and am thrilled at the opportunity to help advance multiple programs for diseases where no treatment options currently exist."

New Leadership Team Appointments

About Encoded

Encoded Therapeutics, Inc., is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. Our mission is to realize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy. We focus on delivering life-changing advances that move away from disease management and towards lasting disease modification. We are advancing our lead asset, ETX101, for the treatment of SCN1A-positiveDravet Syndrome. For more information, please visitwww.Encoded.com.

Media Contacts

Sarah SuttonGlover Park Groupssutton@gpg.com 202-337-0808

Danielle CanteyGlover Park Groupdcantey@gpg.com 202-337-0808

View original content to download multimedia:http://www.prnewswire.com/news-releases/encoded-therapeutics-expands-gene-therapy-leadership-with-key-appointment-and-promotion-301002272.html

SOURCE Encoded Therapeutics, Inc.

See the original post:
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion - Yahoo Finance

Why sequencing the human genome failed to produce big breakthroughs in disease – The Conversation US

An emergency room physician, initially unable to diagnose a disoriented patient, finds on the patient a wallet-sized card providing access to his genome, or all his DNA. The physician quickly searches the genome, diagnoses the problem and sends the patient off for a gene-therapy cure. Thats what a Pulitzer prize-winning journalist imagined 2020 would look like when she reported on the Human Genome Project back in 1996.

The Human Genome Project was an international scientific collaboration that successfully mapped, sequenced and made publicly available the genetic content of human chromosomes or all human DNA. Taking place between 1990 and 2003, the project caused many to speculate about the future of medicine. In 1996, Walter Gilbert, a Nobel laureate, said, The results of the Human Genome Project will produce a tremendous shift in the way we can do medicine and attack problems of human disease. In 2000, Francis Collins, then head of the HGP at the National Institutes of Health, predicted, Perhaps in another 15 or 20 years, you will see a complete transformation in therapeutic medicine. The same year, President Bill Clinton stated the Human Genome Project would revolutionize the diagnosis, prevention and treatment of most, if not all, human diseases.

It is now 2020 and no one carries a genome card. Physicians typically do not examine your DNA to diagnose or treat you. Why not? As I explain in a recent article in the Journal of Neurogenetics, the causes of common debilitating diseases are complex, so they typically are not amenable to simple genetic treatments, despite the hope and hype to the contrary.

The idea that a single gene can cause common diseases has been around for several decades. In the late 1980s and early 1990s, high-profile scientific journals, including Nature and JAMA, announced single-gene causation of bipolar disorder, schizophrenia and alcoholism, among other conditions and behaviors. These articles drew massive attention in the popular media, but were soon retracted or failed attempts at replication. These reevaluations completely undermined the initial conclusions, which often had relied on misguided statistical tests. Biologists were generally aware of these developments, though the follow-up studies received little attention in popular media.

There are indeed individual gene mutations that cause devastating disorders, such as Huntingtons disease. But most common debilitating diseases are not caused by a mutation of a single gene. This is because people who have a debilitating genetic disease, on average, do not survive long enough to have numerous healthy children. In other words, there is strong evolutionary pressure against such mutations. Huntingtons disease is an exception that endures because it typically does not produce symptoms until a patient is beyond their reproductive years. Although new mutations for many other disabling conditions occur by chance, they dont become frequent in the population.

Instead, most common debilitating diseases are caused by combinations of mutations in many genes, each having a very small effect. They interact with one another and with environmental factors, modifying the production of proteins from genes. The many kinds of microbes that live within the human body can play a role, too.

Since common serious diseases are rarely caused by single-gene mutations, they cannot be cured by replacing the mutated gene with a normal copy, the premise for gene therapy. Gene therapy has gradually progressed in research along a very bumpy path, which has included accidentally causing leukemia and at least one death, but doctors recently have been successful treating some rare diseases in which a single-gene mutation has had a large effect. Gene therapy for rare single-gene disorders is likely to succeed, but must be tailored to each individual condition. The enormous cost and the relatively small number of patients who can be helped by such a treatment may create insurmountable financial barriers in these cases. For many diseases, gene therapy may never be useful.

The Human Genome Project has had an enormous impact on almost every field of biological research, by spurring technical advances that facilitate fast, precise and relatively inexpensive sequencing and manipulation of DNA. But these advances in research methods have not led to dramatic improvements in treatment of common debilitating diseases.

Although you cannot bring your genome card to your next doctors appointment, perhaps you can bring a more nuanced understanding of the relationship between genes and disease. A more accurate understanding of disease causation may insulate patients against unrealistic stories and false promises.

[ Youre smart and curious about the world. So are The Conversations authors and editors. You can read us daily by subscribing to our newsletter. ]

Here is the original post:
Why sequencing the human genome failed to produce big breakthroughs in disease - The Conversation US

Medtech is a different beast than biotech in the life sciences pack – STAT

Biotech innovations dominate the life science news cycle think CRISPR for gene editing or CAR-T for cancer immunotherapy. Medical technologies, encompassing the broad swath of devices and interventional technologies, diagnostics, imaging, and digital medicine, tend to make their marks out of the limelight, yet have an enormous impact on public health and offer significant investment opportunities.

Take, for example, the trajectory of interventional cardiology. Open-heart surgery was long considered the only way to restore blood flow limited by a blockage in a coronary artery. The invention of artery-opening angioplasty not only changed that but, along with significant improvements in surgery overall, contributed to a steep decline in deaths due to cardiac disease. Abetting this decline were advances in engineering minimally invasive techniques, better diagnostic stratification of patients for surgery or interventional approaches, and a rise in improvements in anesthetic monitoring and critical care support. The result is good news for people with acute and chronic cardiac conditions.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Originally posted here:
Medtech is a different beast than biotech in the life sciences pack - STAT

Almac and Pfizer slash gene therapy labeling times – OutSourcing-Pharma.com

In 2018, Pfizer initiated a Phase Ib clinical trial of its gene therapy treatment for Duchenne muscular dystrophy (DMD). The AAV9 gene therapy, PF-06939926, is designed to provide DMD patients with a form of the dystrophin gene at the root of the condition, thereby countering the progressive muscle degeneration and weakness that characterizes the disease.

Pfizer planned to dose 15 patients with the gene therapy, which must be stored at -70C. In light of those factors, Pfizer opted for a patient-led supply model that would only ship product once a subject was enrolled and ready for treatment.

The model made the lag between a site requesting and receiving product critical, as during that time patients with a progressive disease would be waiting for a potentially beneficial treatment. Pfizers goal was to package and ship the gene therapy to patients within two weeks.

That goal created challenges. Typically, the lag between the ordering and shipment of trial materials is six to eight weeks. Almac had already reduced that lead time by applying LEAN packaging and labelling principles but needed to shave a further two weeks off to meet Pfizers demands.

To do so, Almacs clinical services unit developed a dedicated packaging and labelling process. The process, which Almac executed at its US facility in Souderton, Pennsylvania, resulted in a 12-day lead time for the first patient enrolled in the trial.

Almac provided the packaging specification within two business days. Pfizer granted approval in one working day. Packaging and labelling took place four to five days after receipt of the initial request.

The case study presented by Almac covers the shipment of a gene therapy to a single patient. Yet, the process it describes has broader relevance for drug developers and contract packagers in an era defined by therapies targeting small patient populations.

In the four years preceding late 2019, the number of clinical trials of advanced therapy medicinal products (ATMP), such as cell and gene therapies, increased by two thirds, according to data tracked by the Alliance for Regenerative Medicine. Many ATMPs place new pressures on supply chains, which are adapting to quickly get medicines to patients.

See the article here:
Almac and Pfizer slash gene therapy labeling times - OutSourcing-Pharma.com

Why Sequencing the Human Genome Failed to Change the Face of Science – The National Interest Online

An emergency room physician, initially unable to diagnose a disoriented patient, finds on the patient a wallet-sized card providing access to his genome, or all his DNA. The physician quickly searches the genome, diagnoses the problem and sends the patient off for a gene-therapy cure. Thats what a Pulitzer prize-winning journalist imagined 2020 would look like when she reported on the Human Genome Project back in 1996.

A new era in medicine?

The Human Genome Project was an international scientific collaboration that successfully mapped, sequenced and made publicly available the genetic content of human chromosomes or all human DNA. Taking place between 1990 and 2003, the project caused many to speculate about the future of medicine. In 1996, Walter Gilbert, a Nobel laureate, said, The results of the Human Genome Project will produce a tremendous shift in the way we can do medicine and attack problems of human disease. In 2000, Francis Collins, then head of the HGP at the National Institutes of Health, predicted, Perhaps in another 15 or 20 years, you will see a complete transformation in therapeutic medicine. The same year, President Bill Clinton stated the Human Genome Project would revolutionize the diagnosis, prevention and treatment of most, if not all, human diseases.

It is now 2020 and no one carries a genome card. Physicians typically do not examine your DNA to diagnose or treat you. Why not? As I explain in a recent article in the Journal of Neurogenetics, the causes of common debilitating diseases are complex, so they typically are not amenable to simple genetic treatments, despite the hope and hype to the contrary.

Causation is complex

The idea that a single gene can cause common diseases has been around for several decades. In the late 1980s and early 1990s, high-profile scientific journals, including Nature and JAMA, announced single-gene causation of bipolar disorder, schizophrenia and alcoholism, among other conditions and behaviors. These articles drew massive attention in the popular media, but were soon retracted or failed attempts at replication. These reevaluations completely undermined the initial conclusions, which often had relied on misguided statistical tests. Biologists were generally aware of these developments, though the follow-up studies received little attention in popular media.

There are indeed individual gene mutations that cause devastating disorders, such as Huntingtons disease. But most common debilitating diseases are not caused by a mutation of a single gene. This is because people who have a debilitating genetic disease, on average, do not survive long enough to have numerous healthy children. In other words, there is strong evolutionary pressure against such mutations. Huntingtons disease is an exception that endures because it typically does not produce symptoms until a patient is beyond their reproductive years. Although new mutations for many other disabling conditions occur by chance, they dont become frequent in the population.

Instead, most common debilitating diseases are caused by combinations of mutations in many genes, each having a very small effect. They interact with one another and with environmental factors, modifying the production of proteins from genes. The many kinds of microbes that live within the human body can play a role, too.

Since common serious diseases are rarely caused by single-gene mutations, they cannot be cured by replacing the mutated gene with a normal copy, the premise for gene therapy. Gene therapy has gradually progressed in research along a very bumpy path, which has included accidentally causing leukemia and at least one death, but doctors recently have been successful treating some rare diseases in which a single-gene mutation has had a large effect. Gene therapy for rare single-gene disorders is likely to succeed, but must be tailored to each individual condition. The enormous cost and the relatively small number of patients who can be helped by such a treatment may create insurmountable financial barriers in these cases. For many diseases, gene therapy may never be useful.

A new era for biologists

The Human Genome Project has had an enormous impact on almost every field of biological research, by spurring technical advances that facilitate fast, precise and relatively inexpensive sequencing and manipulation of DNA. But these advances in research methods have not led to dramatic improvements in treatment of common debilitating diseases.

Although you cannot bring your genome card to your next doctors appointment, perhaps you can bring a more nuanced understanding of the relationship between genes and disease. A more accurate understanding of disease causation may insulate patients against unrealistic stories and false promises.

[ Youre smart and curious about the world. So are The Conversations authors and editors. You can read us daily by subscribing to our newsletter. ]

Ari Berkowitz, Presidential Professor of Biology; Director, Cellular & Behavioral Neurobiology Graduate Program, University of Oklahoma

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image: Reuters

Continue reading here:
Why Sequencing the Human Genome Failed to Change the Face of Science - The National Interest Online

Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium | DNA RNA and Cells | News Channels…

DetailsCategory: DNA RNA and CellsPublished on Thursday, 13 February 2020 10:39Hits: 90

Neurocognitive development of young MPS IIIA patients preserved up to two years post ABO-102 treatment

Dose-dependent and sustained reductions in disease-specific biomarkers denotes clear biologic effects of ABO-102 and ABO-101

First patient treated in cohort 3 of ABO-101 MPS IIIB trial; total enrollment eight patients

Favorable safety profile observed in both studies

NEW YORK, NY and CLEVELAND, OH, USA I February 12, 2020 I Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that researchers from the Abigail Wexner Research Institute (AWRI) at Nationwide Childrens Hospital presented positive interim data from two ongoing Phase I/II clinical trials evaluating ABO-102 and ABO-101, the Companys investigational gene therapies for MPS IIIA and MPS IIIB, respectively, at WORLDSymposium. Results from the Transpher A study demonstrated that MPS IIIA patients younger than 30 months treated with ABO-102 in dose cohort 3 continue to show neurocognitive development 18 months to two years after treatment. Reductions in cerebrospinal fluid (CSF) heparan sulfate (HS), denoting enzyme activity in the central nervous system, and liver volume reductions remain stable two years after treatment. Results from the Transpher B study showed that ABO-101 also improved multiple disease biomarkers providing clear evidence of a biologic effect in patients with MPS IIIB. Dosing in cohort 2 is complete and the first patient in cohort 3 was treated in late January, with a total of 8 patients treated to date. Both therapies have been well-tolerated to date. Abeona licensed the AAV9-based gene therapy technology underpinning ABO-102 and ABO-101 from AWRI at Nationwide Childrens where it was developed.

Todays presentations are available on abeonatherapeutics.com by following this link:https://investors.abeonatherapeutics.com/news-events

In total, the new results continue to show that early treatment with ABO-102 can help preserve neurodevelopment in children with MPS IIIA. These data will inform our ongoing discussions with the FDA and EMA, as we work towards providing a regulatory update in the second quarter, said Joo Siffert, M.D., Chief Executive Officer. For ABO-101, the reductions in disease-specific biomarkers are encouraging and demonstrate a clear biologic effect, which parallels that seen in the MPS IIIA study. We look forward to enrolling the Transpher B study as expeditiously as possible.

Results from the Transpher A study, an ongoing Phase I/II clinical trial with ABO-102 showed that:

The interim results presented today add to evidence suggesting a single intravenous dose of ABO-102 AAV9-based gene therapy has the potential to help MPS IIIA patients sustain neurocognitive development when they are treated at a young age, said Kevin Flanigan, M.D., Director, Center for Gene Therapy at AWRI at Nationwide Children's and Transpher A study investigator. These data showed that ABO-102 can deliver a functional copy of the SGSH gene to cells of the CNS and peripheral organs, as evidenced by the clinical benefits in neurocognition and biophysical measures and improvements in disease-specific biomarkers.

Sites in the U.S., Spain, and Australia continue to enroll eligible patients into the Transpher A study. Additional information about the trial is available at AbeonaTrials.com and ClinicalTrials.gov.

Results from cohorts 1 and 2 (n=7) of the Transpher B study, an ongoing Phase I/II clinical trial showed that ABO-101 treatment demonstrated biologic effect in patients with MPS IIIB, as evidenced by initial improvements in multiple disease biomarkers associated with abnormal accumulation of glycosaminoglycans (GAGs) in the brain and throughout the body:

The Transpher B study provides hope that we may one day alter the course of this devastating disease, said Kim McBride, M.D., Principal Investigator at AWRI at Nationwide Children's and co-investigator for the Transpher B study. The impact on disease biomarkers in the early stages of follow up suggest the potential of ABO-101 gene therapy to break down the accumulation of glycosaminoglycans that underlie MPS IIIB pathology. I look forward to working with fellow investigators to gather more data from the study, including results from high-dose cohort 3.

Dose cohort 2 has been completed and dosing is underway in cohort 3 (n=1). Sites in the U.S., Spain, and France continue to enroll eligible patients into the Transpher B study. Additional information about the trial is available at abeonatherapeutics.com/clinical-trials and ClinicalTrials.gov.

About The Transpher A StudyThe Transpher A Study (NCT02716246) is an ongoing, two-year, open-label, dose-escalation, Phase I/II global clinical trial assessing ABO-102 for the treatment of patients with Sanfilippo syndrome type A (MPS IIIA). The study, also known as ABT-001, is intended for patients 6 months to 2 years of age, or patients older than 2 years with a cognitive Developmental Quotient of 60% or above. The study has enrolled 14 patients to date across three dose-escalating cohorts (N=3, N=3, N=8) and remains open for enrollment. The gene therapy ABO-102 is delivered using AAV9 technology via a single-dose intravenous infusion. The study primary endpoints are neurodevelopment and safety, with secondary endpoints including behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF, plasma and urine, and brain and liver volume.

About The Transpher B StudyThe Transpher B Study (NCT03315182) is an ongoing, two-year, open-label, dose-escalation, Phase I/II global clinical trial assessing ABO-101 for the treatment of patients with Sanfilippo syndrome type B (MPS IIIB). The study, also known as ABT-002, is intended for patients 6 months to 2 years of age, or patients older than 2 years with a cognitive Developmental Quotient of 60% or above. The study has enrolled 8 patients to date across three dose-escalating cohorts (N=2, N=5, N=1) and remains open for enrollment. The gene therapy ABO-101 is delivered using AAV9 technology via a single-dose intravenous infusion. The study primary endpoints are neurodevelopment and safety, with secondary endpoints including behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF, plasma and urine, and brain and liver volume.

About ABO-102ABO-102 is a novel gene therapy in Phase I/II development for Sanfilippo syndrome type A (MPS IIIA), a rare lysosomal storage disease with no approved treatment that primarily affects the central nervous system (CNS). ABO-102 is dosed in a one-time intravenous infusion using a self-complementary AAV9 vector to deliver a functional copy of the SGSH gene to cells of the CNS and peripheral organs. The therapy is designed to address the underlying SGSH enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain and throughout the body that results in progressive cell damage and neurodevelopmental and physical decline. In the U.S., Abeona holds Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations for the ABO-102 clinical program. In the EU, the Company holds PRIME and Orphan medicinal product designations.

About ABO-101ABO-101 is a novel gene therapy in Phase I/II development for Sanfilippo syndrome type B (MPS IIIB), a rare lysosomal storage disease with no approved therapy that primarily affects the central nervous system (CNS). ABO-101 is dosed in a one-time intravenous infusion using a self-complementary AAV9 vector to deliver a functional copy of the NAGLU gene to cells of the CNS and peripheral tissues. The therapy is designed to address the underlying NAGLU enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain and throughout the body that results in progressive cell damage and neurodevelopmental and physical decline. In the U.S., Abeona holds Fast Track and Rare Pediatric Disease designations for ABO-101 and Orphan Drug designation in both the U.S. and EU.

About Sanfilippo Syndrome Type A (MPS IIIA)Sanfilippo syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease with no approved treatment that primarily affects the CNS and is characterized by rapid neurodevelopmental and physical decline. Children with MPS IIIA present with progressive language and cognitive decline and behavioral abnormalities. Other symptoms include sleep problems and frequent ear infections. Additionally, distinctive facial features with thick eyebrows or a unibrow, full lips and excessive body hair for ones age, and liver/spleen enlargement are also present in early childhood. MPS IIIA is caused by genetic mutations that lead to a deficiency in the SGSH enzyme responsible for breaking down glycosaminoglycans, which accumulate in cells throughout the body resulting in rapid health decline associated with the disorder.

About Sanfilippo syndrome type B (MPS IIIB)Sanfilippo syndrome type B (MPS IIIB) is a rare and fatal lysosomal storage disease with no approved therapy that primarily affects the central nervous system and is characterized by rapid neurodevelopmental and physical decline. Children with MPS IIIB present with progressive language and cognitive decline and behavioral abnormalities. Other symptoms include sleep problems and frequent ear infections. Additionally, distinctive signs such as facial features with thick eyebrows or a unibrow, full lips and excessive body hair for ones age and liver/spleen enlargement are also present. The underlying cause of MPS IIIB is a deficiency in the NAGLU enzyme responsible for breaking down glycosaminoglycans, which accumulate throughout the body resulting in rapid decline associated with the disorder.

About Abeona TherapeuticsAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Companys clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Companys portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates, including Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). http://www.abeonatherapeutics.com

SOURCE: Abeona Therapeutics

The rest is here:
Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium | DNA RNA and Cells | News Channels...

Vapers Show Chemical Changes in Their Genome Linked to Cancer – Global Health News Wire

This is the latest study from a Keck School of Medicine of USC research team to show e-cigarette users develop cancer-related molecular changes similar to smokers. Image Credit: CASEY CHIN

Biologically important changes in DNA seen in smokers are also being found in people who vape, according to a new study published in the journalEpigenetics.

A team of scientists at the Keck School of Medicine of USC have found people who vape exhibit similar chemical modifications in their overall genome and in parts of their DNA as people who smoke cigarettes.

These specific chemical alterations, also known as epigenetic changes, can cause genes to malfunction and are commonly found in nearly all types of human cancer as well as other serious diseases.

The findings add to a growing list of health concerns associated with vaping, which is perceived by many as a safer alternative to smoking. E-cigarette use has soared among youth, with more than 25 percent of high school students now using the products, according to the CDC.

The new study, led by Ahmad Besaratinia, PhD, associate professor at the Keck School of Medicine of USC, examined a group of people matched for age, gender and race, divided equally into three categories: vapers only, smokers only and a control group of people who neither vaped nor smoked.

Blood was drawn from each of the participants and tested for changes in levels of two specific chemical tags attached to DNA that are known to impact gene activity and/or function. These chemical tags include: (1) methyl groups in a specific DNA sequence, named Long Interspersed Nucleotide Element 1 (LINE-1); and (2) hydroxymethyl groups in the genome overall. Changes in the levels of these chemical tags, which are important for genomic stability and regulation of gene expression, occur in various stages of development, as well as in diseases such as cancer.

Of the 45 study participants, vapers and smokers both showed significant reduction in the levels of both chemical tags compared to the control group. This is the first study to show that vapers, like smokers, have these biologically important changes detectable in their blood cells.

That doesnt mean that these people are going to develop cancer, said Besaratinia. But what we are seeing is that the same changes in chemical tags detectable in tumors from cancer patients are also found in people who vape or smoke, presumably due to exposure to cancer-causing chemicals present in cigarette smoke and, generally at much lower levels, in electronic cigarettes vapor.

This is the newest study Besaratinias team has done on vapers and smokers. Their earlier study published last year (IJMS, 2019) examined changes in gene expression in epithelial cells taken from the mouths of vapers and smokers compared to a control group. In that study, both vapers and smokers showed abnormal gene expression in a large number of genes linked to cancer.

Our new study adds an important piece to that puzzle by demonstrating that epigenetic mechanisms, specifically changes in chemical tags attached to the DNA, may contribute to the abnormal expression of genes in vapers and smokers alike, said Besaratinia.

He and his team plan to continue their research. The next step is to look at the whole genome and identify all the genes targeted by these two chemical changes in vapers versus smokers.

Considering the established role many genes play in human diseases, this investigation should provide invaluable information, which may have immediate public health and policy implications, said Besaratinia. The epidemic of teen vaping and the recent outbreak of vaping-related severe lung injury and deaths in the U.S. underscore the importance of generating scientific evidence on which future regulations for electronic cigarette manufacturing, marketing, and distribution can be based.

Originally posted here:
Vapers Show Chemical Changes in Their Genome Linked to Cancer - Global Health News Wire

Press Registration Reminder! Countdown to the 2020 ACMG Annual Clinical Genetics Meeting – PRNewswire

BETHESDA, Md., Feb. 12, 2020 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) heads to a new destination in sunny San Antonio, Texas in 2020. Named one of the fastest growing meetings in the USA by Trade Show Executive Magazine, the ACMG Annual Clinical Genetics Meeting continues to provide groundbreaking research and news about the latest advances in genetics, genomics and personalized medicine. To be held March 17-21, the 2020 ACMG Annual Meeting will feature more than 40 scientific sessions as well as three Short Courses, a variety of workshops, TED-Style talks and satellite symposia, and more than 750 poster presentations on emerging areas of genetic and genomic medicine.

Interview those at the forefront in medical genetics and genomics, connect in person with new sources and get story ideas on the clinical practice of genetics and genomics in healthcare today and for the future. Learn how genetics and genomics research is being integrated and applied into medical practice.

Topics include gene editing, cancer genetics, molecular genomics, exome sequencing, pre- and perinatal genetics, biochemical/metabolic genetics, genetic counseling, health services and implementation, legal and ethical issues, therapeutics and more.

Credentialed media representatives on assignment are invited to attend and cover the ACMG Annual Meeting on a complimentary basis. Contact Reymar Santos at rsantos@acmg.net for the Press Registration Invitation Code, which will be needed to register at http://www.acmgmeeting.net.

Abstracts of presentations are available online at http://www.acmgmeeting.net. A few 2020 ACMG Annual Meeting highlights include:

Program Highlights:

Cutting-Edge Scientific Concurrent Sessions:

Three Half-Day Genetics Short Courses on Monday, March 16 and Tuesday, March 17:

Photo/TV Opportunity: The ACMG Foundation for Genetic and Genomic Medicine will present bicycles to local children with rare genetic diseases at the Annual ACMG Foundation Day of Caring on Friday, March 20 from 10:30 AM 11:00 AM at the Henry B. Gonzlez Convention Center.

Social Media for the 2020 ACMG Annual Meeting: As the ACMG Annual Meeting approaches, journalists can stay up to date on new sessions and information by following the ACMG social media pages on Facebook, Twitterand Instagramand by usingthe hashtag #ACMGMtg20 for meeting-related tweets and posts.

Note be sure to book your hotel reservations early.

The ACMG Annual Meeting website has extensive information at http://www.acmgmeeting.net.

About the American College of Medical Genetics and Genomics (ACMG) and the ACMG Foundation for Genetic and Genomic Medicine

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,400 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Raye Alford, PhD ralford@acmg.net

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

Read the original post:
Press Registration Reminder! Countdown to the 2020 ACMG Annual Clinical Genetics Meeting - PRNewswire

Research Roundup: CRISPR-based cancer therapy, tanning studies, immigration and deportation – The Stanford Daily

Each week, The Dailys Science & Tech section produces a roundup of the most exciting and influential research happening on campus or otherwise related to Stanford. Heres our digest for the week of Feb. 2 Feb. 8.

CRISPR-based cancer therapy shows promise

A new FDA-approved cancer therapy uses the gene-editing technology Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to enhance T-cells, a type of immune cell, in order to better fight cancer, a study published on Feb. 6 in Science found.

Lets say normally, theres a T-cell thats involved in an allergic reaction to pollen, genetics and dermatology professor Howard Chang told Stanford Medicines blog SCOPE. We can use CRISPR to alter the cell so that it doesnt react to pollen anymore, and instead, only fights cancer.

The researchers goal was to introduce three gene edits to T-cells, then reintroduce edited T-cells back into the patient. The gene edits would rid T-cells of their natural receptors and increase their immune activity to actively fight cancer. After three months, researchers took edited T-cell samples from patients to analyze their molecular characteristics.

If you think of all of these edited T-cells like theyre in a horse race, analyzing these cells is like being able to see which horse wins the race, but also that horses speed, gait and all of the critical details that make that horse the best, Chang told Stanford Medicines blog SCOPE.

The findings suggest the therapy is safe, and further studies will need to be performed in future human clinical trials.

Industry-backed studies show bias favoring indoor tanning

Studies on indoor tanning that are financially backed by the tanning industry are more likely to promote benefits and dismiss risks compared to studies without financial support, an investigation published on Feb. 4 in the British Medical Journal found.

The association is quite striking, dermatology professor Eleni Linos told Stanford Medicine News. We need scientific data to be independent of industry influence. I am concerned that funding sources may influence the conclusions of these papers.

The researchers analyzed 691 journal articles referencing indoor tanning and found that 50 had industry backing. 78% of articles with industry backing portrayed indoor tanning in a positive light, compared to 4% of articles without industry backing.

This is the first study to examine conflict of interest in indoor tanning literature, and it echoes whats been said about the influence of the tobacco and sugar industries on science, Linos told Stanford Medicine News. Researchers, public health experts and members of the general public should be aware of and account for industry funding when assessing the evidence related to the risks and benefits of indoor tanning.

Immigrants who obtain legal status might still fear deportation

Immigrants might continue to fear deportation even after receiving documentation, a study published on Jan. 29 in Law & Society Review found.

Documentation is hardly a shield from deportation fears, sociology assistant professor Asad Asad told Stanford News. Documentation affords some protection from deportation, but it can also heighten fears since the bureaucracies that document immigrants have a greater perceived ability to surveil and expel them.

Between 2013 to 2015, he conducted extensive interviews with 50 undocumented and documented immigrants living in the Dallas metropolitan area to learn about their everyday lives.

Some undocumented migrants may be chilled out of legalization opportunities in an attempt to maintain a sense of invisibility to a system they view as primarily punitive, Asad told Stanford News. If fears of deportation lead immigrants to pass up rare opportunities for legal status in their search for invisibility from a system they view as unforgiving, they and their U.S.-citizen children may face restricted opportunities for promoting their long-term well-being in this country.

Contact Derek Chen at derekc8 at stanford.edu.

More:
Research Roundup: CRISPR-based cancer therapy, tanning studies, immigration and deportation - The Stanford Daily

Sangamo Therapeutics Appoints John Markels to Its Board of Directors – BioSpace

Feb. 12, 2020 13:00 UTC

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general management, manufacturing and technology experience at Merck, to the Sangamo Board of Directors.

"We are very pleased to welcome John to our Board," said Sandy Macrae, Chief Executive Officer of Sangamo. Johns manufacturing expertise and global general management and therapeutic area leadership experience will greatly benefit Sangamo as we build out our own in-house gene and cell therapy manufacturing capabilities and advance our innovative pipeline of genomic medicine product candidates toward registration and eventual commercialization.

Dr. Markels has over 30 years of leadership experience in the pharmaceutical industry. He currently serves as President of Global Vaccines at Merck, a role in which he leads an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio. Earlier roles at Merck included President, Latin America, as well as a long career in senior leadership positions in major regions worldwide in manufacturing technology, operations and strategy, business development, alliance management, and supply chain. Dr. Markels received his Ph.D. in chemical engineering from the University of California, Berkeley and his B.S. in chemical engineering from the University of Delaware.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit http://www.sangamo.com.

Forward Looking Statements

This press release contains or refers to forward-looking statements regarding Sangamo's current expectations. These forward-looking statements include, without limitation, statements regarding the potential benefits of cell therapy, the Company's ability to develop and commercialize product candidates to address genetic diseases with the Company's proprietary technologies and the timing of commencement or next stages of such programs and the anticipated benefits therefrom. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on March 1, 2019 and Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 that it filed on November 6, 2019. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005263/en/

Link:
Sangamo Therapeutics Appoints John Markels to Its Board of Directors - BioSpace

Where’s Rock Bottom for Predictive Technology Group Inc (OTCMKTS:PRED)? – The Oracle Dispatch

Predictive Technology Group Inc (OTCMKTS:PRED) just announced that it and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrins and other small molecule ATR inhibitors.

According to the release, Atrinand Predictive will jointly utilize Predictive Laboratories state-of-the-artsequencing capabilities and genomics expertise to identify cancer patients withspecific molecular markers that predict the level of clinical response toAtrins, and other, targeted therapies. This is intended to improve patientoutcomes as well as improve Atrins ability to successfully progress itsproduct pipeline, and upon commercialization, improve on the treatments forwomen with cancer.

Predictive Technology Group Inc (OTCMKTS:PRED) promulgates itself as a company that, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps).

The company was formerly knownas Global Enterprises Group, Inc. and changed its name to Predictive TechnologyGroup, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005and is headquartered in Salt Lake City, Utah.

The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT.

According to companymaterials, Predictive Technology Group aims to revolutionize patient carethrough predictive data analytics, novel gene-based diagnostics and companiontherapeutics through its subsidiaries Predictive Therapeutics, PredictiveBiotech, and Predictive Laboratories. These subsidiaries are focused onendometriosis, scoliosis, degenerative disc disease and human cell and tissueproducts. The subsidiaries use genetic and other information as cornerstones inthe development of new diagnostics that assess a persons risk of illness andtherapeutic products designed to identify, prevent and treat diseases moreeffectively.

Find out when $PRED reaches critical levels. Subscribe toOracleDispatch.com Right Now by entering your Email in the box below.

As noted above, PRED just announced that it and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrins and other small molecule ATR inhibitors.

Even in light of this news, PRED has had a rough past week of trading action, with shares sinking something like -2% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Moreover, the stock has seen interest climb, with an increase in recent trading volume of 12% beyond what we have been seeing over the larger time frame.

We are very pleased to workwith Atrin Pharmaceuticals, a recognized leader in the development ofanti-cancer therapeutics targeting DDR, said Bradley Robinson, president andchief executive officer of Predictive Technology Group. We see an opportunityto develop a precision medicine approach to address unmet medical needs bycombining our state-of-the-art sequencing capabilities, genomics expertise andcompanion diagnostics with Atrins targeted therapeutics. This collaboration isconsistent with our vision of building a leading womens health platform, andwe look forward to working together on this important initiative.

Earning a current market capvalue of $252M, PRED has a stash ($842K) ofcash on the books, which compares with about $8.6M in total currentliabilities. PRED is pulling in trailing 12-month revenues of $43.7M. Inaddition, the company is seeing major top-line growth, with y/y quarterlyrevenues growing at 2.4%. You can bet we will update this one again as newinformation comes into view. Sign-up forcontinuing coverage on shares of $PRED stock, as well as other hot stock picks,get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $PRED, either long orshort, and we have not been compensated for this article.

You have Successfully Subscribed!

Post Views: 127

See the article here:
Where's Rock Bottom for Predictive Technology Group Inc (OTCMKTS:PRED)? - The Oracle Dispatch

These Alternative Treatments May Be The Answer To The Pain Of Aging – HuffPost

Illustration by Sara Andreasson for HuffPost

This story is part of Pain in America, a nine-part series looking at some of the underlying causes of the opioid addiction crisis and how we treat pain.

With age comes pain. Whether caused by injury, arthritis, cancer or any number of conditions, persistent pain affects up to four out of every five people age 65 and older.

While many turn to opioids and other medications, their risks, including the potential for abuse and overdose, are well known. Less well known (at least among the general public) are the added issues older adults can face when taking these drugs.

The older you are, the more likely you are to develop an adverse side effect from a pain medication, said Cary Reid, associate professor of medicine in the division of geriatric and palliative medicine at Weill Cornell Medicine and director at Cornells Translational Research Institute on Pain in Later Life (TRIPLL).

Those side effects, such as confusion and a heightened risk of falls, can be severe and can make doctors hesitant to prescribe pain medications to older adults. These drugs can also take longer to metabolize with age, meaning they can be more potent or stay in an elderly persons system longer than expected. And because many older adults take other medications too, theres also the risk of problematic drug interactions.

With the number of American seniors expected to almost double by 2060 to nearly a quarter of the population this all adds up to a growing need to find alternative treatments.

Thats where researchers like those at TRIPLL come in. One of 13 Roybal Centers that the U.S. governments National Institute on Aging has funded to improve the lives of older Americans, TRIPLL focuses on nondrug approaches to managing and preventing chronic pain.

Its casting a wide net, looking into alternatives that range from acupuncture and meditation to physical therapy, cognitive behavioral therapy and even mobile technologies.

Reporting Pain With Digital Health Technology

In one TRIPLL-funded project, Elizabeth Murnane, a postdoctoral scholar in the computer science department at Stanford University, and a team of researchers developed smartphone-based technology that adults 55 and older can use to self-report the intensity of chronic pain. The idea is to capture information about pain as it happens without burdening the patient, while serving as an alternative to pen-and-paper and verbal self-reporting measures commonly used in clinical settings or at-home methods that often suffer from low adherence or misreporting.

The test used nine different measures to capture the patients experience of pain, including a circle that fills with color when the interface is touched, and a widget for reporting pain with a numerical range of 0 to 10 that can be adjusted by tapping the screen. Early testing revealed some usability issues for older adults with low digital skills or motor, cognitive and visual impairments, so the researchers changed the design to be more touch and pressure-oriented, in part motivated by how wed sometimes observe our participants instinctually grasping the hand of a loved one or a chair or other object nearby in moments of pain, Murnane explained.

Now Murnane and her collaborators are working on a pain assessment tool that examines rhythms of pain intensity.

Many factors can influence the experience of pain age, gender, genes and how much sleep a person needs (and how much they actually get), Murnane said. Healthy functioning and synchronization of the circadian system is known to deteriorate with age, contributing to a vicious cycle of sleep disruption and exacerbated pain in older adults.

The researchers hope the data can be used to advance the basic understanding of pain and how it manifests in everyday life behaviorally, psychologically and physiologically as well as to design new tools for pain monitoring and management. For example, they hope to discover digital biomarkers of pain, which are bits of data collected with digital devices and wearables like smartwatches that can be used to explain or predict the presence of illness or disease. In Murnanes case, these markers could be someones degree of forward flexion or how far theyve walked on an inclined path, which researchers expect would correlate with pain severity, she said.

Emotion Regulation Therapy

Negative emotions are also associated with chronic pain typically, the more depression, anger, negativity and irritability that a patient feels, the more pain they report experiencing, Reid explained.

Weill Cornell Medicine psychologist Dimitris Kiosses and a multidisciplinary team of researchers have been working on a psychosocial treatment called problem adaptation therapy that aims to provide elderly patients suffering from chronic pain with techniques like deep breathing, relaxation and changing their perspective on a situation to decrease the impact of negative emotions and increase the impact of positive ones.

The goal there is to have people recognize the kinds of emotions they experience and to develop strategies to minimize negative emotions, because research has demonstrated a strong link between negative emotions and increased pain and pain-related disability, Reid said.

Barbara Chase, an 81-year-old New York City resident, learned valuable techniques for managing chronic back and nerve pain she experiences from Parkinsons disease by participating in this program. Shes never liked taking medicine, she said, and is amazed by how helpful some nondrug alternatives like listening to music and relaxing her body and mind can be in managing pain. Chase now likes to go to the gym, turn off the lights, and listen to music through her phone while stretching and doing other movement exercises, which she says takes her to another place.

It makes me relax and I just forget, Chase said. I dont think about it.

Relaxing by lying on the floor, closing her eyes, and spreading out like a bird has a similar effect, she said, adding that she can often feel her pain coming on ahead of time, and now knows to use these emotion-regulation techniques to get rid of it.

Its amazing, she said. And its free.

Behavioral Treatment For Older Adults With HIV

Older adults with HIV are a growing population with high rates of chronic pain and substance use, and decreased physical function. To address these issues, researchers supported by TRIPLL developed an eight-week behavioral pilot study in 2016 that incorporated weekly tai chi and cognitive behavioral therapy sessions and used text messaging to facilitate behavior change.

Results from a small randomized control trial were positive participants who took part in the CBT, tai chi and texting program experienced more pain relief, reduced substance use and improved physical performance compared to a control group who received standard care. Now the researchers are trying to obtain funding from the National Institutes of Health to support a similar but much larger trial.

Looking To The Future

Because many clinicians were trained to manage pain primarily with medication, educating them about nondrug approaches to pain management can be difficult, Reid said.

Another challenge is getting insurers to cover nonpharmacological pain management techniques, and without insurance coverage, many treatments become inaccessible for patients who cant afford the out-of-pocket costs.

Even finding places that offer those alternatives can be tough. Its often difficult in New York City, and if its difficult in New York City, imagine what it must be like if youre living in a very rural state, Reid said. Weve got to enhance the availability and dissemination of these kinds of tools.

Read more from the original source:

These Alternative Treatments May Be The Answer To The Pain Of Aging - HuffPost